Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: A randomized controlled trial

Wiener Klinische Wochenschrift

Volumn 121, Issue 23-24, 2009, Pages 765-775

  Petrica, Ligia ^a   Petrica, Maxim ^a   Vlad, Adrian ^a   Dragos Jianu, Catalin ^a   Gluhovschi, Gheorghe ^a   Ianculescu, Calina ^a   Dumitrascu, Victor ^a   Giju, Sorin ^a   Gluhovschi, Cristina ^a   Bob, Flaviu ^a   Ursoniu, Sorin ^a   Gadalean, Florica ^a   Velciov, Silvia ^a   Bozdog, Gheorghe ^a   Marian, Roxana ^a  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

Author keywords

Biomarkers; Nephroprotection; Neuroprotection; Proximal tubule dysfunction; Rosiglitazone

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; CYSTATIN C; FIBRINOGEN; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; METFORMIN; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; MALE; MIDDLE CEREBRAL ARTERY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION;

ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 77249111716     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-009-1279-3     Document Type: Article

References (57)

1. ME Molitch RA DeFronzo MJ Franz WF Keane CE Mogensen HH Parving, et al. 2004 Nephropathy in diabetes Diabetes Care 27 Suppl 1 S79 S83 14693934
2. G Schernthaner 2008 Kidney disease in diabetology: lessons from 2007 Nephrol Dial Transplant 23 1112 1115 10.1093/ndt/gfn060 18359869 (Pubitemid 351767534)
3. T Dorner T Rathmanner M Lechleitner R Schlögel M Roden K Lawrence, et al. 2006 Public health aspects of diabetes mellitus epidemiology, prevention strategies, policy implications: the first Austrian diabetes report Wien Klin Wochenschr 118 513 519 10.1007/s00508-006-0666-2 17009062 (Pubitemid 44579742)
4. CA Schneider E Ferrannini R Defronzo G Schernthaner J Yates E Erdmann 2008 Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease J Am Soc Nephrol 19 182 187 10.1681/ASN.2007060678 1:CAS:528:DC%2BD1cXhs12hu70%3D 18057215
5. WB Kannel DL McGee 1979 Diabetes and cardiovascular disease The Framingham study. JAMA 241 2035 2038 1:STN:280:DyaE1M7lsVCksg%3D%3D
6. HJ Kramer QD Nguyen G Curhan CY Hsu 2003 Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus JAMA 289 3273 3277 10.1001/jama.289.24.3273 12824208 (Pubitemid 37430080)
7. RJ MacIsaac C Tsalamandris S Panagiotopoulos TJ Smith KJ McNeil G Jerums 2004 Nonalbuminuric renal insufficiency in type 2 diabetes Diabetes Care 27 195 200 10.2337/diacare.27.1.195 14693989 (Pubitemid 38196732)
8. WD Comper D Haraldsson WM Deen 2008 Resolved: normal glomeruli filter nephrotic levels of albumin J Am Soc Nephrol 19 427 432 10.1681/ASN.2007090997 18216311 (Pubitemid 351355385)
9. LM Russo RM Sandoval SB Campos BA Molitoris WD Comper D Brown 2009 Impaired tubular uptake explains albuminuria in early diabetic nephropathy J Am Soc Nephrol 20 489 494 10.1681/ASN.2008050503 19118149
10. BA Perkins LH Ficociello BE Ostrander KH Silva J Weinberg JH Warram, et al. 2007 Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes J Am Soc Nephrol 18 1353 1361 10.1681/ASN.2006080872 1:CAS:528:DC%2BD2sXkslSrtrw%3D 17329575 (Pubitemid 46536923)
11. RP Donahue S Stranges K Rejman LB Rafalson J Dmochowski M Trevisan 2007 Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study Diabetes Care 30 1724 1729 10.2337/dc07-0040 1:CAS:528: DC%2BD2sXotlWhsbo%3D 17456840 (Pubitemid 47036343)
12. BW Lee SH Ihm MG Choi HJ Yoo 2007 The comparison of cystatin C and creatinine as an accurate serum marker in the prediction of type 2 diabetic nephropathy Diabetes Res Clin Pract 78 428 434 10.1016/j.diabres.2007.06.015 1:CAS:528:DC%2BD2sXht12gur%2FJ 17822797 (Pubitemid 350030986)
13. Yang YS, Peng CH, Lin CK, Wang CP, Huang CN (2007) Use of serum cystatin C to detect early decline of glomerular filtration rate in type 2 diabetes. Intern Med DOI 10.2169/internalmedicine.46. 6081:801-806
14. M Mussap M Dalla Vestra P Fioretto A Saller M Varagnolo R Nosadini, et al. 2002 Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients Kidney Int 61 1453 1461 10.1046/j.1523-1755.2002.00253.x 1:CAS:528:DC%2BD38XjtVGqtLw%3D 11918752 (Pubitemid 34304506)
15. SA Aksun D Ozmen B Ozmen Z Parildar I Mutaf N Turgan, et al. 2004 B2-microglobulin and cystatin C in type 2 diabetes: assessment of diabetic nephropathy Exp Clin Endocrinol Diabetes 112 195 200 10.1055/s-2004-817933 1:CAS:528:DC%2BD2cXjvFelu74%3D 15127324 (Pubitemid 38639290)
16. CY Hong K Hughes KS Chia V Ng SL Ling 2003 Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore Diabetes Care 26 338 342 10.2337/diacare.26.2.338 1:CAS:528:DC%2BD3sXhs1ynu74%3D 12547859 (Pubitemid 36929052)
17. P Holmquist O Torffvit 2008 Tubular function in diabetic children assessed by Tamm-Horsfall protein and glutathione S-transferase Pediatr Nephrol 23 1079 1083 10.1007/s00467-008-0770-9 18351395
18. S Uslu B Efe O Alatas N Kebapçi O Colak C Demirüstü, et al. 2005 Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients J Nephrol 18 559 567 1:CAS:528: DC%2BD28XosVShug%3D%3D 16299682
19. A Kalansooriya I Holbrook P Jennings PH Whiting 2007 Serum cystatin C, enzymuria, tubular proteinuria and early renal insult in type 2 diabetes Br J Biomed Sci 64 121 123 1:CAS:528:DC%2BD2sXhtFGgt7jI 17910281
20. PA Sarafidis GL Bakris 2006 Protection of the kidney by thiazolidinediones: an assessment from bench to bedside Kidney Int 70 1223 1233 10.1038/sj.ki.5001620 1:CAS:528:DC%2BD28Xpsl2qsLk%3D 16883325 (Pubitemid 44435173)
21. DJ Stocker AJ Taylor RW Langley MR Jezior RA Vigersky 2007 A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes Am Heart J 153 445.e1 445.e6 10.1016/j.ahj.2006.11.005 (Pubitemid 46343533)
22. GL Bakris LM Ruilope SO McMorn WM Weston MA Heise MI Freed, et al. 2006 Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria J Hypertens 24 2047 2055 10.1097/01.hjh.0000244955.39491.88 1:CAS:528:DC%2BD28XptFWhsL4%3D 16957566 (Pubitemid 44371272)
23. Y Miyazaki E Cersosimo C Triplitt RA DeFronzo 2007 Rosiglitazone decreases albuminuria in type 2 diabetic patients Kidney Int 72 1367 1373 10.1038/sj.ki.5002516 1:CAS:528:DC%2BD2sXhtlWjtrrL 17805239 (Pubitemid 350126770)
24. HN Hodis WJ Mack L Zheng Y Li M Torres D Sevilla, et al. 2006 Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes Diabetes Care 29 1545 1553 10.2337/dc05-2462 1:CAS:528:DC%2BD28XnsVahur0%3D 16801577 (Pubitemid 44127579)
25. H Koshiyama D Shimono N Kuwamura J Minamikawa Y Nakamura 2001 Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes J Clin Endocrinol Metab 86 3452 3456 10.1210/jc.86.7.3452 1:CAS:528:DC%2BD3MXlt1Gju7k%3D 11443224 (Pubitemid 32673521)
26. MR Langenfeld T Forst C Hohberg P Kann G Lübben T Konrad, et al. 2005 Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study Circulation 111 2525 2531 10.1161/01.CIR.0000165072. 01672.21 1:CAS:528:DC%2BD2MXjvFOisrw%3D 15883215 (Pubitemid 40696142)
27. T Mazzone PM Meyer SB Feinstein MH Davidson GT Kondos RB D'Agostino, et al. 2006 Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 296 2572 2581 10.1001/jama.296.21.joc60158 1:CAS:528:DC%2BD28Xht12lsbbM 17101640 (Pubitemid 44903861)
28. T Nakamura T Matsuda Y Kawagoe H Ogawa Y Takahashi K Sekizuka, et al. 2004 Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients Metabolism 53 1382 1386 10.1016/j.metabol.2004.05.013 1:CAS:528:DC%2BD2cXnslehtro%3D 15375799 (Pubitemid 39222104)
29. T Shimazu I Inoue N Araki Y Asano M Sawada D Furuya, et al. 2005 A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia Stroke 36 353 359 10.1161/01.STR. 0000152271.21943.a2 1:CAS:528:DC%2BD2MXmtVWhsg%3D%3D 15618443 (Pubitemid 40170822)
30. K Tureyen R Kapadia KK Bowen I Satriotomo J Liang DL Feinstein, et al. 2007 Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normo-glycemic as well as hypertensive and type-2 diabetic rodents J Neurochem 101 41 56 10.1111/j.1471-4159.2006.04376.x 1:CAS:528:DC%2BD2sXksFSqsLk%3D 17394460 (Pubitemid 46426485)
31. Y Luo W Yin AP Signore F Zhang Z Hong S Wang, et al. 2006 Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone J Neurochem 97 435 448 10.1111/j.1471-4159. 2006.03758.x 1:CAS:528:DC%2BD28XksVykt7c%3D 16539667
32. K Schmerbach JH Schefe M Krikov S Müller A Villringer U Kintscher, et al. 2008 Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain Brain Res 1208 225 233 10.1016/j.brainres.2008.02.032 1:CAS:528:DC%2BD1cXlsFOjt78%3D 18378216
33. T Nakamura E Yamamoto K Kataoka T Yamashita Y Tokutomi YF Dong, et al. 2007 Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure Stroke 38 3016 3022 10.1161/STROKEAHA.107.486522 1:CAS:528:DC%2BD2sXhtF2itbnJ 17885259 (Pubitemid 350041562)
34. J Lee M Reding 2007 Effects of thiazolidinediones on stroke recovery: a case-matched controlled study Neurochem Res 32 635 638 10.1007/s11064-006-9138-3 1:CAS:528:DC%2BD2sXjtlynurw%3D 16960755 (Pubitemid 46481294)
35. B Charbonnel J Dormandy E Erdmann M Massi-Benedetti A Skene PROactive Study Group 2004 The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients Diabetes Care 27 1647 1653 10.2337/diacare.27.7.1647 15220241 (Pubitemid 38857439)
36. R Wilcox MG Bousser DJ Betteridge G Schernthaner V Pirags S Kupfer, et al. 2007 Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) Stroke 38 865 873 10.1161/01.STR.0000257974.06317.49 1:CAS:528:DC%2BD2sXhslygur8%3D 17290029 (Pubitemid 46568445)
37. L Ryden E Standl M Bartnik G Van den Berghe J Betteridge MJ de Boer Task Force Members 2007 Guidelines on diabetes and cardiovascular disease of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 88 136 10.1093/eurheartj/ehm124 1:CAS:528:DC%2BD2sXitlaiur8%3D 17220161 (Pubitemid 47355991)
38. AS Levey KU Eckardt Y Tsukamoto A Levin J Coresh J Rossert, et al. 2005 Definition and classification of chronic kidney disease: a position statement from Kidney Disease Improving Outcomes (KDIGO) Kidney Int 67 2098 2100 10.1111/j.1523-1755.2005.00365.x (Pubitemid 41623371)
39. Valdueza JM, Schreiber SJ, Roehl JE, Klingebiel R (2008) Neurosonology and neuroimaging of stroke. Georg Thieme, Stuttgart
40. Lindegaard KF (1992) Indices of pulsatility. In: Newell DW, Aaslid R (eds) Transcranial Doppler. Raven Press Publishers, New York, pp 67-82
41. SE Kahn SM Haffner MA Heise WH Herman RR Holman NP Jones ADOPT Study Group, et al. 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427 2443 10.1056/NEJMoa066224 1:CAS:528:DC%2BD28Xht12ntrzF 17145742 [Erratum, N Engl J Med 2007; 356: 1387] (Pubitemid 44903747)
42. F Pistrosch K Herbrig B Kindel J Passauer S Fischer P Gross 2005 Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients Diabetes 54 2206 2211 10.2337/diabetes.54.7.2206 1:CAS:528:DC%2BD2MXmtVelt78%3D 15983223 (Pubitemid 40911285)
43. MG Shlipak R Katz MJ Sarnak LF Fried AB Newman C Stehman-Breen, et al. 2006 Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease Ann Intern Med 145 237 246 1:CAS:528:DC%2BD28XpsFejtb0%3D 16908914
44. HJ Kim DJ Kang DJ Kim SH Kim CW Ahn BS Cha, et al. 2007 Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-β in type 2 diabetes mellitus Clin Endocrinol (Oxf) 66 282 289 10.1111/j.1365-2265.2006.02723.x 1:CAS:528:DC%2BD2sXjsF2ntLc%3D (Pubitemid 46096150)
45. Abdin AA, Baalash AA, Hamooda HE (2009) Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers. J Diabetes Complications [Epub ahead of print]
46. AM Lincoff K Wolski SJ Nicholls SE Nissen 2007 Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 1180 1188 10.1001/jama.298.10.1180 1:CAS:528:DC%2BD2sXhtVGmtL3J 17848652 (Pubitemid 47403104)
47. R Wilcox S Kupfer E Erdmann PROactive Study investigators 2008 Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In MacroVascular Events (PROactive 10) Am Heart J 155 712 717 10.1016/j.ahj.2007. 11.029 1:CAS:528:DC%2BD1cXktVChtr8%3D 18371481
48. SE Nissen K Wolski 2007 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457 2471 10.1056/NEJMoa072761 1:CAS:528:DC%2BD2sXms1SisrY%3D 17517853 [Erratum, N Engl J Med 2007; 357: 100] (Pubitemid 46919772)
49. PD Home SJ Pocock H Beck-Nielsen R Gomis M Hanefeld NP Jones RECORD Study Group, et al. 2007 Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis N Engl J Med 357 28 38 10.1056/NEJMoa073394 1:CAS:528:DC%2BD2sXnsVCqs7w%3D 17551159 (Pubitemid 47026732)
50. PJ Touboul A Elbaz C Koller C Lucas V Adraï F Chédru, et al. 2000 Common carotid artery intima-media thickness and brain infarction: the Etude du Profil Génétique de l'Infarctus Cérébral (GENIC) case-control study. The GENIC Investigators Circulation 102 313 318 1:STN:280:DC%2BD3czmtVWnsg%3D%3D 10899095
51. M Davidson PM Meyer S Haffner S Feinstein R D'Agostino Sr GT Kondos, et al. 2008 Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus Circulation 117 2123 2130 10.1161/CIRCULATIONAHA.107.746610 1:CAS:528:DC%2BD1cXks1Gjsb4%3D 18413496 (Pubitemid 351572171)
52. B Hedblad A Zambanini P Nilsson L Janzon G Berglund 2007 Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study J Intern Med 261 293 305 10.1111/j.1365-2796.2007.01767.x 1:CAS:528:DC%2BD2sXksVSjsbw%3D 17305652 (Pubitemid 46255951)
53. I Tkac M Troscak M Javorsky R Petrik M Tomcova 2001 Increased intracranial arterial resistance in patients with type 2 diabetes mellitus Wien Klin Wochenschr 113 870 873 1:CAS:528:DC%2BD38Xlt1yjtQ%3D%3D 11762124
54. KY Lee HS Young JS Baik GW Kim JS Kim 2000 Arterial pulsatility as an index of cerebral microangiopathy in diabetes Stroke 31 1111 1115 1:STN:280:DC%2BD3c3lvFOlsA%3D%3D 10797173
55. L Petrica M Petrica M Munteanu A Vlad F Bob C Gluhovschi, et al. 2007 Cerebral microangiopathy in patients with non-insulin-dependent diabetes mellitus Ann Acad Med Singapore 36 259 266 17483855
56. L Petrica M Petrica A Vlad F Bob C Gluhovschi Gh Gluhovschi, et al. 2007 Cerebrovascular reactivity is impaired in patients with non-insulin-dependent diabetes mellitus and microangiopathy Wien Klin Wochenschr 119 365 371 10.1007/s00508-007-0809-0 17634895 (Pubitemid 47087508)
57. JS Park MH Cho KY Lee CS Kim HJ Kim JS Nam, et al. 2007 The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus Metabolism 56 1081 1086 10.1016/j.metabol.2007.03.017 1:CAS:528:DC%2BD2sXnsFKqtbo%3D 17618953 (Pubitemid 47021172)